| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ying Zhang, Shengzhu Sun, Yunhong Nin. Post-marketing safety surveillance of vortioxetine hydrobromide: a pharmacovigilance study leveraging FAERS database. Frontiers in psychiatry. vol 16. 2025-03-11. PMID:40066137. |
vortioxetine hydrobromide is a widely prescribed medication for the treatment of major depressive disorder (mdd), primarily exerting its antidepressant effects by inhibiting the reuptake of serotonin (5-ht).the objective of this study was to investigate adverse events (aes) associated with vortioxetine hydrobromide through data mining in the fda adverse event reporting system (faers) to enhance clinical safety. |
2025-03-11 |
2025-03-13 |
Not clear |
| Isabella Berardelli, Elena Rogante, Federico Formica, Riccardo Iannazzo, Attilio Valerio Mammoliti, Raffaele Riccioni, Skender Veizi, Roger S McIntyre, Maurizio Pompil. The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis. Journal of psychopharmacology (Oxford, England). 2025-02-01. PMID:39891526. |
the efficacy of vortioxetine in the acute treatment of major depressive disorder: a systematic review and meta-analysis. |
2025-02-01 |
2025-02-04 |
Not clear |
| Isabella Berardelli, Elena Rogante, Federico Formica, Riccardo Iannazzo, Attilio Valerio Mammoliti, Raffaele Riccioni, Skender Veizi, Roger S McIntyre, Maurizio Pompil. The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis. Journal of psychopharmacology (Oxford, England). 2025-02-01. PMID:39891526. |
among the available pharmacological treatments for acute major depressive disorder (mdd), vortioxetine, a serotonin transporter inhibitor (sert), has been widely used for its multimodal action on serotonin neurotransmission, which produces essential changes also on glutamate, gamma amino butyric acid (gaba), norepinephrine, acetylcholine, and dopamine. |
2025-02-01 |
2025-02-04 |
Not clear |
| Xinyi Ye, Pengfeng Xu, Jianping Jiao, Haoyang Zhao, Kangyu Jin, Shiyi Zhang, Fen Pan, Jingkai Chen, Hao Jiang, Jianbo Hu, Manli Huan. A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality. Neuropsychiatric disease and treatment. vol 20. 2024-12-10. PMID:39654656. |
to assess the efficacy and safety of vortioxetine and escitalopram in improving cognition in patients with major depressive disorder (mdd). |
2024-12-10 |
2024-12-12 |
Not clear |
| Lue-En Lee, Kuo-Hsuan Chun. Vortioxetine-Induced Bleeding Tendency in a Young Woman with Depression: A Case Report. Psychiatry and clinical psychopharmacology. 2024-12-04. PMID:39629743. |
vortioxetine, which functions as a 5-ht3, 5-ht1d, and 5-ht7 antagonist, a 5-ht1a agonist, and a 5-ht1b partial agonist, is a recently launched antidepressant approved by the united states food and drug administration for treating adult major depressive disorder. |
2024-12-04 |
2024-12-06 |
Not clear |
| Seok Woo Moon, Jee Wook Kim, Do Hoon Kim, Michael Adair, Daniel Oudin Åström, Elin Heldbo Reines, Minah Lee, Gayoung Ki. Vortioxetine in the Treatment of Major Depressive Disorder Among Working Patients in Routine Clinical Practice: An Analysis of a Post-Marketing Surveillance Study in South Korea. Neuropsychiatric disease and treatment. vol 20. 2024-12-02. PMID:39619493. |
vortioxetine in the treatment of major depressive disorder among working patients in routine clinical practice: an analysis of a post-marketing surveillance study in south korea. |
2024-12-02 |
2024-12-06 |
Not clear |
| Bassem Badr, Hana Al Gailani, Samia Alkhoori, Hania Butt, Michel Daher, Bassam Dheyaa, Nasser El Hindy, Mohamed Wafeek Eid, Nisrin Elsaadouni, Valentina Faia, Alaa Haweel, Tarek Khammas, Hussein Omar, George Tadros, Charles Yacoub, Tamer Talaat, Ahmed El-Shafe. Effectiveness of 8-week TReatment with vortioxetine on depressive symptoms in major depressive disorder patients with comorbid generalized anxiety disorder in UAE (TRUE). Annals of general psychiatry. vol 23. issue 1. 2024-11-02. PMID:39487479. |
effectiveness of 8-week treatment with vortioxetine on depressive symptoms in major depressive disorder patients with comorbid generalized anxiety disorder in uae (true). |
2024-11-02 |
2024-11-05 |
Not clear |
| Michael Cronquist Christensen, Iria Grande, Andreas Rieckmann, Pratap Chokk. Efficacy of vortioxetine versus desvenlafaxine in the treatment of functional impairment in patients with major depressive disorder: Results from the multinational VIVRE study. CNS spectrums. 2024-10-28. PMID:39463173. |
efficacy of vortioxetine versus desvenlafaxine in the treatment of functional impairment in patients with major depressive disorder: results from the multinational vivre study. |
2024-10-28 |
2024-10-30 |
Not clear |
| Michael Cronquist Christensen, Iria Grande, Andreas Rieckmann, Pratap Chokk. Efficacy of vortioxetine versus desvenlafaxine in the treatment of functional impairment in patients with major depressive disorder: Results from the multinational VIVRE study. CNS spectrums. 2024-10-28. PMID:39463173. |
in vivre (nct04448431), vortioxetine was associated with significantly higher rates of symptomatic and functional remission, better daily and social functioning, and greater treatment satisfaction than desvenlafaxine in patients with major depressive disorder (mdd) and partial response to selective serotonin reuptake inhibitor (ssri) therapy. |
2024-10-28 |
2024-10-30 |
Not clear |
| José María García-Alberca, Paz De La Guia, Esther Gris, Silvia Mendoza, María Lopez De La Rica, Miguel Ángel Barbancho, José Pablo Lara, Encarnación Blanco-Rein. Effectiveness of Vortioxetine Treatment on Depression and Cognitive Functions in Patients with Alzheimer's Disease: A 12-Month, Retrospective, Observational Study. Journal of personalized medicine. vol 14. issue 9. 2024-09-28. PMID:39338172. |
this study aimed to assess the effectiveness of vortioxetine for improving depressive symptoms, cognitive performance, daily and global functioning in patients with alzheimer's disease (ad) and major depressive disorder (mdd) in real-world clinical practice. |
2024-09-28 |
2024-10-01 |
Not clear |
| N Simple Santi, Sashi B Biswal, Birendra Narayan Naik, Jyoti Prakash Sahoo, Bhabagrahi Rat. A Randomized Controlled Trial Comparing the Effects of Vilazodone, Escitalopram, and Vortioxetine Monotherapy on the Metabolic Parameters in Patients With Major Depressive Disorder. Cureus. vol 16. issue 8. 2024-09-27. PMID:39328643. |
a randomized controlled trial comparing the effects of vilazodone, escitalopram, and vortioxetine monotherapy on the metabolic parameters in patients with major depressive disorder. |
2024-09-27 |
2024-09-29 |
Not clear |
| Gia Han Le, Sabrina Wong, Andy Lu, Shreya Vasudeva, Hartej Gill, Sebastian Badulescu, Daylen Rodriguez Portelles, Yang Jing Zheng, Kayla M Teopiz, Shakila Meshkat, Angela T H Kwan, Roger Ho, Taeho Greg Rhee, Joshua D Rosenblat, Rodrigo B Mansur, Roger S McIntyr. Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review. Journal of affective disorders. 2024-09-19. PMID:39299586. |
electroencephalography (eeg) spectral signatures of selective serotonin reuptake inhibitors (ssris), selective norepinephrine reuptake inhibitors (snris) and vortioxetine in major depressive disorder: a systematic review. |
2024-09-19 |
2024-09-22 |
Not clear |
| Eduardo Cerchi Barbosa, Giovanna Hanike Santos da Silva, Ângelo Eduardo Espíndola Sbardelotto, Douglas Carneiro Barroso, Fernanda Ribeiro de Lima, Loyná Euá Flores E Paez, Saulo Bernardo Lança, Arthur Bezerra Cavalcanti Petrucci, Felipe Bandeira de Melo Guimarães, Antônio Leandro Nasciment. Vortioxetine versus reuptake inhibitors in adults with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. Asian journal of psychiatry. vol 101. 2024-09-14. PMID:39276484. |
vortioxetine versus reuptake inhibitors in adults with major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. |
2024-09-14 |
2024-09-18 |
Not clear |
| Eduardo Cerchi Barbosa, Giovanna Hanike Santos da Silva, Ângelo Eduardo Espíndola Sbardelotto, Douglas Carneiro Barroso, Fernanda Ribeiro de Lima, Loyná Euá Flores E Paez, Saulo Bernardo Lança, Arthur Bezerra Cavalcanti Petrucci, Felipe Bandeira de Melo Guimarães, Antônio Leandro Nasciment. Vortioxetine versus reuptake inhibitors in adults with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. Asian journal of psychiatry. vol 101. 2024-09-14. PMID:39276484. |
although vortioxetine demonstrates superior efficacy relative to placebo, there is still a lack of robust evidence to determine whether it offers advantages over commonly prescribed antidepressants for treating major depressive disorder (mdd). |
2024-09-14 |
2024-09-18 |
Not clear |
| Joshua T Jordan, Li Shen, Nicholas J Cooper, Samantha V Goncalves, Madhukar H Trivedi, Alan F Schatzberg, Wei Wu, Adam J Savitz, Amit Etki. Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine for Major Depressive Disorder: Findings From Placebo-Controlled Trials. The Journal of clinical psychiatry. vol 85. issue 4. 2024-09-06. PMID:39240698. |
baseline cognition is not associated with depression outcomes in vortioxetine for major depressive disorder: findings from placebo-controlled trials. |
2024-09-06 |
2024-09-09 |
Not clear |
| Melissa P DelBello, Robert L Findling, Michael Huss, Oscar Necking, Maria L Petersen, Simon N Schmidt, Monika Rose. Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies. European child & adolescent psychiatry. 2024-09-06. PMID:39240359. |
vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies. |
2024-09-06 |
2024-09-08 |
human |
| Ping Wang, Wei-Wei Wang, Yi-Qi Liu, Wen-Qiang Li, Jian-Xin Hu, Yun-Ai Su, Ji-Tao Li, Nan Li, Tian-Mei S. The dose-response relationship of vortioxetine on major depressive disorder: an umbrella review. Psychiatry research. vol 340. 2024-08-09. PMID:39121757. |
the dose-response relationship of vortioxetine on major depressive disorder: an umbrella review. |
2024-08-09 |
2024-08-13 |
Not clear |
| Ping Wang, Wei-Wei Wang, Yi-Qi Liu, Wen-Qiang Li, Jian-Xin Hu, Yun-Ai Su, Ji-Tao Li, Nan Li, Tian-Mei S. The dose-response relationship of vortioxetine on major depressive disorder: an umbrella review. Psychiatry research. vol 340. 2024-08-09. PMID:39121757. |
vortioxetine is a novel multimodal antidepressant, but its precise efficacy and dose-response relationship for treating different symptoms in major depressive disorder (mdd) is still unclear. |
2024-08-09 |
2024-08-13 |
Not clear |
| Michael Adair, Rohini Bose, Simon Nitschky Schmid. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study. Current medical research and opinion. 2024-08-07. PMID:39110846. |
safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in india: results from an interventional, flexible-dose study. |
2024-08-07 |
2024-08-10 |
Not clear |
| Michael Adair, Rohini Bose, Simon Nitschky Schmid. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study. Current medical research and opinion. 2024-08-07. PMID:39110846. |
vortioxetine has demonstrated safety and efficacy in improving symptoms of major depressive disorder (mdd), including overall functioning in real-world settings. |
2024-08-07 |
2024-08-10 |
Not clear |